*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | Effects of 12-week whole-body vibration training versus resistance training in older people with sarcopenia Scientific reports · human | PMID 40011687 |
| 2025 | Effects of Resistance Training on Muscular Adaptations and Inflammatory Markers in Overweight and Obese Men Medicine and science in sports and exercise · human | PMID 39809255 |
| 2024 | The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation Metabolism: clinical and experimental · preclinical | PMID 39481534 |
| 2024 | Effectiveness of low-load resistance training with blood flow restriction vs. conventional high-intensity resistance training in older people diagnosed with sarcopenia: a randomized controlled trial Scientific reports · human | PMID 39558011 |
| 2024 | A molecular pathway for cancer cachexia-induced muscle atrophy revealed at single-nucleus resolution Cell reports · preclinical | PMID 39116208 |
| 2024 | Supplementing With Which Form of Creatine (Hydrochloride or Monohydrate) Alongside Resistance Training Can Have More Impacts on Anabolic/Catabolic Hormones, Strength and Body Composition? Physiological research · human | PMID 39545789 |
| 2023 | Metabolic crosstalk between skeletal muscle cells and liver through IRF4-FSTL1 in nonalcoholic steatohepatitis Nature communications · preclinical | PMID 37770480 |
| 2023 | Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy Neuromuscular disorders : NMD · preclinical | PMID 36689846 |
| 2022 | Myostatin: Basic biology to clinical application Advances in clinical chemistry · preclinical | PMID 35152972 |
| 2022 | Depletion of CD206(+) M2-like macrophages induces fibro-adipogenic progenitors activation and muscle regeneration Nature communications · preclinical | PMID 36411280 |
| 2022 | Serum Myostatin and Follistatin Levels in Patients With Dermatomyositis and Polymyositis Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · preclinical | PMID 34740999 |
| 2021 | Effects of 16 Weeks of Resistance Training on Muscle Quality and Muscle Growth Factors in Older Adult Women with Sarcopenia: A Randomized Controlled Trial International journal of environmental research and public health · human | PMID 34201810 |
| 2021 | Myostatin and Follistatin-New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications Biomedicines · preclinical | PMID 34680417 |
| 2020 | The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review Nutrients · preclinical | PMID 32604889 |
| 2019 | Activin type II receptor signaling in cardiac aging and heart failure Science translational medicine · preclinical | PMID 30842316 |
Follistatin-344 (Follistatin-344). Glycoprotein that binds and neutralises myostatin (and other TGF-beta family members), removing the brake on muscle growth in preclinical models.
Commonly discussed uses: muscle-growth / muscular-dystrophy research (preclinical/gene-therapy context). The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Note: most uses are not approved indications.
Mechanism: Glycoprotein that binds and neutralises myostatin (and other TGF-beta family members), removing the brake on muscle growth in preclinical models.
Reported considerations: no human safety data for injected peptide, theoretical: off-target TGF-beta effects. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Preclinical/gene-therapy research target. Injected-peptide use is unvalidated. Not approved. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low research-defined, typical no established safe human dose, high unknown. Administration: subcutaneous/intramuscular (anecdotal, unvalidated). Half-life: short for the protein; gene-therapy approaches differ.
Australian status: Not ARTG-registered; research. Preclinical/gene-therapy research target. Injected-peptide use is unvalidated. Not approved. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research-defined; storage: frozen aliquots.
Commonly discussed combinations (anecdotal for unapproved compounds): experimental anabolic protocols (anecdotal, high-uncertainty). Stacking increases interaction/safety uncertainty.